Outfitter Financial LLC Has $757,000 Stock Position in Novo Nordisk A/S (NYSE:NVO)

Outfitter Financial LLC boosted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 9.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 8,795 shares of the company’s stock after acquiring an additional 795 shares during the quarter. Outfitter Financial LLC’s holdings in Novo Nordisk A/S were worth $757,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Natixis Advisors LLC increased its holdings in shares of Novo Nordisk A/S by 2.7% in the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after purchasing an additional 80,070 shares in the last quarter. Norman Fields Gottscho Capital Management LLC boosted its position in Novo Nordisk A/S by 45.3% in the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock valued at $5,482,000 after buying an additional 19,870 shares during the last quarter. Versant Capital Management Inc acquired a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at $86,000. Talbot Financial LLC bought a new stake in shares of Novo Nordisk A/S during the fourth quarter worth $4,066,000. Finally, Clear Creek Financial Management LLC acquired a new position in shares of Novo Nordisk A/S during the fourth quarter valued at $450,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 0.5 %

Shares of NYSE NVO opened at $83.79 on Friday. Novo Nordisk A/S has a twelve month low of $77.82 and a twelve month high of $148.15. The stock has a market cap of $376.02 billion, a price-to-earnings ratio of 25.47, a P/E/G ratio of 0.90 and a beta of 0.45. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The company’s fifty day moving average is $86.39 and its 200-day moving average is $108.48.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Equities research analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be paid a dividend of $0.7874 per share. This represents a yield of 1.2%. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio is presently 21.88%.

Analyst Upgrades and Downgrades

NVO has been the subject of several recent research reports. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. BMO Capital Markets cut their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. Finally, Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Novo Nordisk A/S has an average rating of “Moderate Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.